Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by Rubric Capital Management LP

Rubric Capital Management LP boosted its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 15.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 23,000,000 shares of the company’s stock after acquiring an additional 3,000,000 shares during the period. Roivant Sciences accounts for 6.4% of Rubric Capital Management LP’s portfolio, making the stock its 2nd largest position. Rubric Capital Management LP owned 3.11% of Roivant Sciences worth $243,110,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ROIV. Charles Schwab Investment Management Inc. grew its holdings in shares of Roivant Sciences by 5.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,023,027 shares of the company’s stock valued at $22,719,000 after buying an additional 99,148 shares during the period. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Roivant Sciences by 26.7% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 18,742 shares of the company’s stock valued at $210,000 after buying an additional 3,955 shares during the period. Norges Bank acquired a new position in shares of Roivant Sciences in the 4th quarter valued at $41,506,000. Dynamic Technology Lab Private Ltd grew its holdings in shares of Roivant Sciences by 35.1% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 17,155 shares of the company’s stock valued at $193,000 after buying an additional 4,458 shares during the period. Finally, Decheng Capital LLC acquired a new position in shares of Roivant Sciences in the 4th quarter valued at $14,371,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ROIV. Bank of America boosted their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a report on Wednesday, September 11th. Piper Sandler boosted their price objective on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Thursday. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.39.

Roivant Sciences Trading Up 0.4 %

Shares of NASDAQ:ROIV opened at $11.97 on Friday. The company’s 50-day moving average price is $11.46 and its two-hundred day moving average price is $11.06. The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.91. Roivant Sciences Ltd. has a one year low of $8.24 and a one year high of $13.24. The stock has a market capitalization of $8.84 billion, a PE ratio of 2.37 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The company had revenue of $55.10 million for the quarter, compared to analyst estimates of $30.72 million. During the same period in the previous year, the business earned ($0.38) EPS. Roivant Sciences’s revenue for the quarter was up 155.1% compared to the same quarter last year. On average, equities analysts forecast that Roivant Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.